Centessa Pharmaceuticals Reveals Promising Phase 1 Data

Grafa

Sep 10, 2024

Centessa Pharmaceuticals (NASDAQ:CNTA) has announced positive interim results from its ongoing Phase 1 trial of the orexin receptor 2 (OX2R) agonist, ORX750.

Centessa shares jumped 14% in premarket trading.

The study demonstrated that acutely sleep-deprived healthy volunteers who received ORX750 experienced statistically significant increases in wakefulness and favorable safety profiles.

Mean sleep latency for the 2.5 mg dose was 32 minutes compared to 17 minutes for the placebo (p-value = 0.01).

“The early data generated has exceeded our expectations, giving us the confidence to accelerate the program into the next stage of clinical development earlier than anticipated,” said Saurabh Saha MD PhD, Chief Executive Officer of Centessa.

The company plans to initiate Phase 2 studies of ORX750 in patients with narcolepsy type 1, narcolepsy type 2, and idiopathic hypersomnia later in 2024.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2466360944"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2466360944\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2466360944?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-09-10 20:01","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2466360944","market":"us","top_or_hot":-1,"title":"Centessa Pharmaceuticals Reveals Promising Phase 1 Data","media":"Grafa","content":"<html><head></head><body><p class=\"t-img-caption\"><img src=\"https://community-static.tradeup.com/news/a7b50cbda539c1b6af1546dc80d094b6\" alt=\"\" title=\"\" tg-width=\"1920\" tg-height=\"1080\"/></p><p>Centessa Pharmaceuticals (NASDAQ:CNTA) has announced positive interim results from its ongoing Phase 1 trial of the orexin receptor 2 (OX2R) agonist, ORX750.</p><p>Centessa shares jumped 14% in premarket trading.</p><p class=\"t-img-caption\"><img src=\"https://community-static.tradeup.com/news/b9f2d45559333346ba1926ee3f72b6e2\" tg-width=\"790\" tg-height=\"840\"/></p><p>The study demonstrated that acutely sleep-deprived healthy volunteers who received ORX750 experienced statistically significant increases in wakefulness and favorable safety profiles.</p><p>Mean sleep latency for the 2.5 mg dose was 32 minutes compared to 17 minutes for the placebo (p-value = 0.01).</p><p>“The early data generated has exceeded our expectations, giving us the confidence to accelerate the program into the next stage of clinical development earlier than anticipated,” said Saurabh Saha MD PhD, Chief Executive Officer of Centessa.</p><p>The company plans to initiate Phase 2 studies of ORX750 in patients with narcolepsy type 1, narcolepsy type 2, and idiopathic hypersomnia later in 2024.</p><p> </p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Centessa Pharmaceuticals Reveals Promising Phase 1 Data</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCentessa Pharmaceuticals Reveals Promising Phase 1 Data\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1019687050\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/b5820fc70e21f7eb65d05d7a2a3e6c15);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Grafa </p>\n<p class=\"h-time\">2024-09-10 20:01</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><head></head><body><p class=\"t-img-caption\"><img src=\"https://community-static.tradeup.com/news/a7b50cbda539c1b6af1546dc80d094b6\" alt=\"\" title=\"\" tg-width=\"1920\" tg-height=\"1080\"/></p><p>Centessa Pharmaceuticals (NASDAQ:CNTA) has announced positive interim results from its ongoing Phase 1 trial of the orexin receptor 2 (OX2R) agonist, ORX750.</p><p>Centessa shares jumped 14% in premarket trading.</p><p class=\"t-img-caption\"><img src=\"https://community-static.tradeup.com/news/b9f2d45559333346ba1926ee3f72b6e2\" tg-width=\"790\" tg-height=\"840\"/></p><p>The study demonstrated that acutely sleep-deprived healthy volunteers who received ORX750 experienced statistically significant increases in wakefulness and favorable safety profiles.</p><p>Mean sleep latency for the 2.5 mg dose was 32 minutes compared to 17 minutes for the placebo (p-value = 0.01).</p><p>“The early data generated has exceeded our expectations, giving us the confidence to accelerate the program into the next stage of clinical development earlier than anticipated,” said Saurabh Saha MD PhD, Chief Executive Officer of Centessa.</p><p>The company plans to initiate Phase 2 studies of ORX750 in patients with narcolepsy type 1, narcolepsy type 2, and idiopathic hypersomnia later in 2024.</p><p> </p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"CNTA","symbol_name":"Centessa Pharmaceuticals plc","start_time":0,"source_url":"https://grafa.com/news/health-centessa-pharmaceuticals-reveals-promising-phase-1-data-273036?referralcode=A314DFDBE96C354756A893C6E3E02493","article_id":"2466360944","we_media_id":"1019687050","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2466360944","pubTimestamp":1725969713,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Grafa","introduction":"Grafa generates AI-driven data, news and analysis about NYSE, Nasdaq and ASX stocks as well as forex, crypto and economic news. News is generated in near real-time due to Grafa's unique data-led approach to media content generation.","home_visible":1,"id":"1019687050","head_image":"https://static.tigerbbs.com/b5820fc70e21f7eb65d05d7a2a3e6c15"},"summary":"Centessa Pharmaceuticals  has announced positive interim results from its ongoing Phase 1 trial of the orexin receptor 2  agonist, ORX750.The study demonstrated that acutely sleep-deprived healthy volunteers who received ORX750 experienced statistically significant increases in wakefulness and favorable safety profiles.Mean sleep latency for the 2.5 mg dose was 32 minutes compared to 17 minutes for the placebo .“The early data generated has exceeded our expectations, giving us the confidence to accelerate the program into the next stage of clinical development earlier than anticipated,” said Saurabh Saha MD PhD, Chief Executive Officer of Centessa.The company plans to initiate Phase 2 studies of ORX750 in patients with narcolepsy type 1, narcolepsy type 2, and idiopathic hypersomnia later in 2024.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"CNTA":"Centessa Pharmaceuticals plc"},"translate_title":"Centessa Pharmaceuticals公布了有希望的一期数据","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CNTA":1.1},"content_text":"Centessa Pharmaceuticals (NASDAQ:CNTA) has announced positive interim results from its ongoing Phase 1 trial of the orexin receptor 2 (OX2R) agonist, ORX750.Centessa shares jumped 14% in premarket trading.The study demonstrated that acutely sleep-deprived healthy volunteers who received ORX750 experienced statistically significant increases in wakefulness and favorable safety profiles.Mean sleep latency for the 2.5 mg dose was 32 minutes compared to 17 minutes for the placebo (p-value = 0.01).“The early data generated has exceeded our expectations, giving us the confidence to accelerate the program into the next stage of clinical development earlier than anticipated,” said Saurabh Saha MD PhD, Chief Executive Officer of Centessa.The company plans to initiate Phase 2 studies of ORX750 in patients with narcolepsy type 1, narcolepsy type 2, and idiopathic hypersomnia later in 2024.","kind":"news","is_publish_news":true,"is_publish_highlight":true,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}